Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...
Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback